Summary
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy
Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B cost and $1.4B revenue synergy targets.
Kenvue Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 850 | $16,243.5 | $16,354 | $110.5 | 0.68% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 18,468 | $368,010.28 | $355,324.32 | -$12,685.96 | -3.45% |
 Curtis Ellergodt Rothschild Investment LLC | 41,291 | $878,789.79 | $812,193.97 | -$66,595.82 | -7.58% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 249,981 | $4.78M | $4.81M | $30,000.62 | 0.63% |
 Tweedy Browne Tweedy, Browne Company LLC | 72,949 | $1.43M | $1.4M | -$30,924.76 | -2.16% |
Kenvue Inc. (KVUE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Kenvue Inc. ever had a stock split?
Kenvue Inc. Profile
| Household Products Industry | Consumer Staples Sector | Kirk L. Perry CEO | NYSE Exchange | 49177J102 CUSIP |
| US Country | 21,890 Employees | 12 Aug 2026 Last Dividend | - Last Split | 4 May 2023 IPO Date |
Overview
Kenvue Inc. is a global consumer health firm that offers a wide range of healthcare products through its diverse operational segments: Self Care, Skin Health and Beauty, and Essential Health. Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue Inc. delivers a comprehensive portfolio of products designed to improve the wellness and health of consumers around the world. By leveraging well-known brands across its segments, Kenvue provides solutions for everyday health concerns, from pain relief and cold prevention to skincare and baby care.
Products and Services
- Self Care: This segment encompasses products for cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and more. Notable brands include Tylenol for pain relief, Motrin for inflammation, Benadryl for allergies, Nicorette for smoking cessation, Zarbee's and ORSLTM for general wellness, Rhinocort for nasal congestion, Calpol for children's fever and pain, and Zyrtec for 24-hour allergy relief.
- Skin Health and Beauty: Dedicated to maintaining skin health and enhancing beauty, this segment offers products for face and body care, hair care, sun protection, and more. It includes Neutrogena for skincare and acne treatment, Aveeno for moisturizers with natural ingredients, Dr.Ci:Labo for innovative skin solutions, Le Petit Marseillais for shower gels and soaps with enchanting fragrances, Lubriderm for daily moisture, Rogaine for hair regrowth, and OGX for salon-inspired hair care.
- Essential Health: Focusing on essential healthcare needs, this segment provides oral care, baby care, women's health, wound care, among other products. It features Listerine for oral health, Johnson's products for baby care, Band-Aid for wound protection, Stayfree pads, o.b. tampons, and Carefree liners for feminine hygiene, as well as Desitin Diaper Rash cream to soothe and protect infants.
